Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability

被引：0
作者：
Abou Chakra, Mohamad [1 ]
Moussa, Mohamad [2 ]
O'Donnell, Michael A. [1 ]
机构：
[1] Univ IA, Dept Urol, Iowa City, IA 52242 USA
[2] Lebanese Univ, Al Zahraa Hosp, Dept Urol, Beirut, Lebanon
来源：
JOURNAL OF CHEMOTHERAPY | 2024年 / 36卷 / 08期
关键词：
RESCUE THERAPY; DOCETAXEL;
D O I：
10.1080/1120009X.2024.2325765
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：694 / 697
页数：4
相关论文
共 38 条
  • [21] Clinical efficacy of intravesical gemcitabine combined with ubenimex in patients with non-muscle-invasive bladder carcinoma after transurethral resection of bladder tumor
    Shao, Li-Jun
    Wang, Hai-Jiang
    Wang, Jia-Rong
    Yuan, Xiao-Fei
    Sha, Quan
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (05) : 1243 - 1249
  • [22] Treatment Modalities for Non-Muscle Invasive Bladder Cancer: An Updated Review
    Mcnall, Shannon
    Hooper, Kailey
    Sullivan, Travis
    Rieger-Christ, Kimberly
    Clements, Matthew
    CANCERS, 2024, 16 (10)
  • [23] Sequential intravesical gemcitabine and docetaxel for treatment-naı<spacing diaeresis>ve and previously treated intermediate-risk nonmuscle invasive bladder cancer
    McElree, Ian M.
    Orzel, Joanna
    Stubbee, Reid
    Steinberg, Ryan L.
    Mott, Sarah L.
    O'Donnell, Michael A.
    Packiam, Vignesh T.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (12) : 485.e1 - 485.e7
  • [24] Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer
    Steinberg, Ryan L.
    Thomas, Lewis J.
    Brooks, Nathan
    Mott, Sarah L.
    Vitale, Andrew
    Crump, Trafford
    Rao, Mounica Y.
    Daniels, Marcus J.
    Wang, Jonathan
    Nagaraju, Supriya
    DeWolf, William C.
    Lamm, Donald L.
    Kates, Max
    Hyndman, M. Eric
    Kamat, Ashish M.
    Bivalacqua, Trinity J.
    Nepple, Kenneth G.
    O'Donnell, Michael A.
    JOURNAL OF UROLOGY, 2020, 203 (05) : 902 - 908
  • [25] Prognostic role of the neutrophil/lymphocyte ratio in high-risk BCG-naïve non-muscle-invasive bladder cancer treated with intravesical gemcitabine/docetaxel
    Chakra, Mohamad Abou
    Lassila, Riitta
    El Beayni, Nancy
    Mott, Sarah L.
    O'Donnell, Michael A.
    BJU INTERNATIONAL, 2025, 135 (01) : 125 - 132
  • [26] Therapeutic Advances in Bladder Preservation for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
    Lange, Alyssa
    Madiraju, Srigita
    Petros, Firas G.
    CANCERS, 2025, 17 (04)
  • [27] Combination intravesical chemotherapy for non-muscle invasive bladder cancer (NMIBC) as first-line or rescue therapy: where do we stand now?
    Abou Chakra, Mohamad
    Packiam, Vignesh T.
    Duquesne, Igor
    Peyromaure, Michael
    McElree, Ian M.
    O'Donnell, Michael A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2024, 25 (02) : 203 - 214
  • [28] Treatment strategies for the Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer
    Jeong, Seung-hwan
    Ku, Ja Hyeon
    INVESTIGATIVE AND CLINICAL UROLOGY, 2023, 64 (02) : 103 - 106
  • [29] Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    Barlow, LaMont J.
    Benson, Mitchell C.
    CURRENT UROLOGY REPORTS, 2013, 14 (02) : 65 - 70
  • [30] Experience with Newer Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer
    LaMont J. Barlow
    Mitchell C. Benson
    Current Urology Reports, 2013, 14 : 65 - 70
1234